News Releases

Year

Aug 04, 2021

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Commenced Jelmyto geographic expansion

Jul 28, 2021

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

Jelmyto ® granted expedited review in Israel Jelmyto is the only US FDA approved treatment for low-grade upper tract urothelial cancer PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel

Jul 28, 2021

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

Conference Call and Webcast Scheduled for Wednesday, August 4, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Jul 14, 2021

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021 2Q 2021 operating expenses anticipated in the range of $33 to $38 million Full 2Q 2021 financial results and conference call to be reported on Wednesday, August 4, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Jul.

Jul 07, 2021

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 7, 2021-- UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Ladenburg Thalmann Healthcare

Jun 04, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 4, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to

May 25, 2021

UroGen Pharma Announces June 2021 Conference Schedule

PRINCETON, N.J. --(BUSINESS WIRE)--May 25, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in

May 13, 2021

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Jelmyto ® net product revenue of $7.5 million for the first quarter of 2021 New patient starts in March and April of 2021 increased 100% and 165%, respectively, compared to new patient starts in January 2021 Phase 3 ATLAS trial enrollment ongoing with new sites activated in Europe Active platform

May 06, 2021

UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 6, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Mar 18, 2021

UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

Achieved Jelmyto ® net product revenue of $8.0 million for the fourth quarter of 2020; $11.8 million in first seven months of commercialization Initiated ATLAS Phase III trial for UGN-102 and actively enrolling patients with low-grade intermediate risk NMIBC Expanded immuno-oncology pipeline with

Current page 1
Page 2
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on